Horizon Therapeutics Public Limited Company ($HZNP) Stock Forecast: Up 6.3% Today

What is Horizon Therapeutics Public Limited Company?

Horizon Therapeutics (HZNP) is a pharmaceutical company that focuses on the development and commercialization of medicines for rare diseases. The overall market for pharmaceuticals has been quite volatile, with companies constantly seeking mergers and acquisitions to strengthen their positions.

Why is Horizon Therapeutics Public Limited Company going up?

HZNP stock is up 6.3% on Aug 25, 2023 20:30

• The top merger stocks held by fund managers include Horizon Therapeutics, indicating a positive sentiment towards the company's growth prospects.
• Legal experts suggest that the Federal Trade Commission is likely to lose its challenge to the Horizon/Amgen deal, which could have contributed to the bullish movement in HZNP stock.
• A whale investor has taken a bullish stance on Horizon Therapeutics, further supporting the positive market sentiment.
• Speculation about a potential settlement with the Federal Trade Commission over the lawsuit to block the Amgen acquisition has also contributed to the stock's gains.
• Overall, the bullish movement in HZNP stock can be attributed to positive market sentiment driven by merger prospects, legal expectations, and investor confidence.

HZNP Price Chart

HZNP Technical Analysis

HZNP News

Top Merger Stocks Held By Fund Managers, Mid-Q3 2023

Horizon Therapeutics remains top stock held by merger-focused funds for the third consecutive quarter. Read more about top merger stocks held by fund managers.

https://seekingalpha.com/article/4630964-top-merger-stocks-held-by-fund-managers-mid-q3-2023?source=feed_all_articles

FTC likely to lose its challenge to the Horizon/Amgen deal, legal experts say - analyst

The Federal Trade Commission is likely to lose its effort to challenge Amgen''s (AMGN) planned $28 billion acquisition of Horizon Therapeutics (HZNP), according to Oppenheimer, which…

https://seekingalpha.com/news/4006073-ftc-likely-to-lose-its-challenge-to-the-horizonamgen-deal-legal-experts-say-analyst

Check Out What Whales Are Doing With HZNP - Horizon Therapeutics ( NASDAQ:HZNP )

A whale with a lot of money to spend has taken a noticeably bullish stance on Horizon Therapeutics. Looking at options history for Horizon Therapeutics HZNP we detected 11 strange trades.

https://www.benzinga.com/markets/options/23/08/34011428/check-out-what-whales-are-doing-with-hznp

Amgen says FTC case to block Horizon Therapeutics deal `defies logic''

Amgen (AMGN) said that the Federal Trade Commission''s lawsuit to challenge its planned purchase of Horizon Therapeutics (HZNP) defies logic. The plaintiffs come nowhere close to…

https://seekingalpha.com/news/4005582-amgen-says-ftc-case-to-block-horizon-therapeutics-deal-defies-logic

Horizon Therapeutics gains amid speculation on potential FTC settlement on Amgen

Horizon Therapeutics (HZNP) rose 1.1%, at least partly amid some speculation about a potential settlement with the Federal Trade Commission over it lawsuit to block the planned $28…

https://seekingalpha.com/news/4004914-horizon-therapeutics-gains-amid-speculation-on-potential-ftc-settlement-on-amgen

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 7.5% Today

Solana ($SOL) Crypto Forecast: Up 9.0% Today

XRP ($XRP) Crypto Forecast: Up 27.4% Today

Decentraland ($MANA) Crypto Forecast: Up 6.4% Today

Bitcoin SV ($BSV) Crypto Forecast: Down 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 9.4% Today

Cardano ($ADA) Crypto Forecast: Up 15.8% Today

Mantle ($MNT) Crypto Forecast: Up 11.9% Today

Dogecoin ($DOGE) Crypto Forecast: Up 8.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.0% Today

Horizon Therapeutics Public Limited Company Price History

23.05.2023 - HZNP Stock was up 1.1%

• HZNP had a strong bullish movement due to positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.
• The positive results from the study in Japan could potentially lead to increased sales and revenue for HZNP.
• The lawsuit filed by the states to stop Amgen from buying HZNP did not seem to have a significant impact on the bullish movement of HZNP.

15.04.2023 - HZNP Stock was down 5.6%

• HZNP had a strong bearish movement today.
• The short percent of float for HZNP has risen 20.14% since its last report, indicating increased bearish sentiment.
• Unusual options activity suggests that someone with a lot of money took a bearish stance on HZNP.
• The report on the global cystic fibrosis treatment market may have also affected the market movement for HZNP.

25.07.2023 - HZNP Stock was up 6.3%

• The top merger stocks held by fund managers include Horizon Therapeutics, indicating a positive sentiment towards the company's growth prospects.
• Legal experts suggest that the Federal Trade Commission is likely to lose its challenge to the Horizon/Amgen deal, which could have contributed to the bullish movement in HZNP stock.
• A whale investor has taken a bullish stance on Horizon Therapeutics, further supporting the positive market sentiment.
• Speculation about a potential settlement with the Federal Trade Commission over the lawsuit to block the Amgen acquisition has also contributed to the stock's gains.
• Overall, the bullish movement in HZNP stock can be attributed to positive market sentiment driven by merger prospects, legal expectations, and investor confidence.

21.07.2023 - HZNP Stock was up 0.4%

• The bullish movement in HZNP today can be attributed to the following factors:
• 1. Bullish options trades: The presence of bullish options trades indicates that large investors have taken a positive stance on Horizon Therapeutics, potentially driving up the stock price.
• 2. Uncertainty surrounding Amgen deal: The confusion surrounding the $28.5 billion acquisition deal between Horizon Therapeutics and Amgen could have caused some volatility in the stock price. However, improved outlook for Horizon Therapeutics and positive Q2 results may have alleviated concerns, leading to a bullish market movement.
• 3. Potential growth from acquisition: The pending acquisition of Horizon Therapeutics by Amgen has the potential to make the company much bigger. This anticipation of growth may have attracted investors, contributing to the bullish movement in the stock.
• Overall, the bullish market movement in HZNP today can be attributed to positive investor sentiment, improved outlook, and the potential growth opportunity presented by the pending acquisition deal with Amgen.